Genomic profiling is a key tool in the treatment of cancer and the study of oncology and other disease areas. By accelerating the process and automating steps, genomic profiles can be generated and accessed more rapidly in the clinic, and reproducibility can be improved in research. But how can this be done? And what are the potential impacts? Andy Felton is the vice president of product management for clinical next-generation sequencing and oncology at Thermo Fisher Scientific (MA, USA). Thermo Fisher Scientific is one of the world’s largest scientific tool providing companies. Andy’s division is specifically involved with producing and...
To view this content, please register now for access
Join our member community for FREE to access a collection of journal and online-only features, including:
- Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
- The latest news and journal updates delivered straight to your inbox when you want it
- Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
- Priority registration to webinars, panel discussions and events
- Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!